These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19110022

  • 1. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
    Kapteyn JC, Porre AM, de Rond EJ, Hessels WB, Tijms MA, Kessen H, Slotboom AM, Oerlemans MA, Smit D, van der Linden J, Schoen P, Thus JL.
    Vaccine; 2009 Feb 25; 27(9):1468-77. PubMed ID: 19110022
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays.
    Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, Li X, Girard M.
    Vaccine; 2011 Apr 18; 29(18):3377-89. PubMed ID: 21397719
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns.
    Garcia-Cañas V, Lorbetskie B, Girard M.
    J Chromatogr A; 2006 Aug 11; 1123(2):225-32. PubMed ID: 16677659
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, Chou AH, Chao HJ, Gu A, Wu SC, Chong P, Lee MS.
    Vaccine; 2008 Oct 23; 26(45):5736-40. PubMed ID: 18761387
    [Abstract] [Full Text] [Related]

  • 10. Conformationally selective biophysical assay for influenza vaccine potency determination.
    Wen Y, Han L, Palladino G, Ferrari A, Xie Y, Carfi A, Dormitzer PR, Settembre EC.
    Vaccine; 2015 Oct 05; 33(41):5342-5349. PubMed ID: 26348403
    [Abstract] [Full Text] [Related]

  • 11. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection.
    García-Cañas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M.
    Anal Chem; 2007 Apr 15; 79(8):3164-72. PubMed ID: 17361989
    [Abstract] [Full Text] [Related]

  • 12. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E.
    Vaccine; 2009 Aug 27; 27(39):5393-401. PubMed ID: 19596415
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A hemagglutinin quantification method for development of an influenza pandemic vaccine using size exclusion high performance liquid chromatography.
    Roh HS, Song HM, Yun BR, Kang HK, Choi KS, Park YJ, Kim DS, Kim SH, Mo IP, An BS, Ahn CY.
    Mol Med Rep; 2015 Apr 27; 11(4):2819-24. PubMed ID: 25482872
    [Abstract] [Full Text] [Related]

  • 15. Developing cell culture-derived pandemic vaccines.
    Barrett PN, Portsmouth D, Ehrlich HJ.
    Curr Opin Mol Ther; 2010 Feb 27; 12(1):21-30. PubMed ID: 20140813
    [Abstract] [Full Text] [Related]

  • 16. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
    Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O, Cornelissen L, Goudsmit J, Barclay W.
    Vaccine; 2009 Apr 28; 27(19):2588-93. PubMed ID: 19428865
    [Abstract] [Full Text] [Related]

  • 17. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation.
    Saito T, Nakaya Y, Suzuki T, Ito R, Saito T, Saito H, Takao S, Sahara K, Odagiri T, Murata T, Usui T, Suzuki Y, Tashiro M.
    J Med Virol; 2004 Oct 28; 74(2):336-43. PubMed ID: 15332284
    [Abstract] [Full Text] [Related]

  • 18. HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
    Fulvini AA, Tuteja A, Le J, Pokorny BA, Silverman J, Bucher D.
    Vaccine; 2021 Jan 15; 39(3):545-553. PubMed ID: 33341306
    [Abstract] [Full Text] [Related]

  • 19. New vaccine approaches for seasonal and pandemic influenza.
    Palache B.
    Vaccine; 2008 Nov 18; 26(49):6232-6. PubMed ID: 18674583
    [Abstract] [Full Text] [Related]

  • 20. Development and qualification of the parallel line model for the estimation of human influenza haemagglutinin content using the single radial immunodiffusion assay.
    van Kessel G, Geels MJ, de Weerd S, Buijs LJ, de Bruijni MA, Glansbeek HL, van den Bosch JF, Heldens JG, van den Heuvel ER.
    Vaccine; 2012 Jan 05; 30(2):201-9. PubMed ID: 22107849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.